About this Journal Publication ethics Editorial Board Editorial Council Editorial Office For the Authors Contacts
English

News feeds

Journal in Databases

eLIBRARY.RU - ÍÀÓ×ÍÀß ÝËÅÊÒÐÎÍÍÀß ÁÈÁËÈÎÒÅÊÀ

Google Scholar

Google Scholar

Main
Validation of efficiency of the government subsidies increase for outpatient pharmaceuticals in Russian Federation Print
Friday, 02 December 2011

Ulumbekova G.E.
Association of Medical Societies for Quality of Medical Care and Medical Education, Moscow

Summary. In this article the effectiveness of increased expenditures on outpatient pharmaceuticals is proved on the bases of the analysis of health indices of the population of Russian Federation and spending on outpatient pharmaceuticals in comparison with the OECD countries.

The importance of such increase arises from unsatisfactory health status of Russian population. In Russian Federation crude death mortality rate is 27% higher, than it was in 1990 and is in «new» EU countries today. Total morbidity is also high – it is 1,5 times higher than it was in 1990. Especially unsatisfactory health status in RF is among working age group of population and among children. Thus, premature (preventable) mortality is 1,8 times higher than in «new» EU countries, which have the same GDP per capita as RF.

In EU countries the 2 fold decrease in mortality during the last 20 years was achieved due to massive healthy lifestyle programs and availability of highly effective medical drugs to treat hypertension, ischemic heart disease, ulcer etc. sponsored by the government.

Today the expenses on outpatient medical drugs in Russia are subsidized by government only for 3.5% of population. They are mainly the patients, suffering from chronic diseases and disabled. At the same time, in the OECD countries the majority of citizens, to whom the doctor has prescribed a medical drug, have the right to receive them free of charge or with partial ”co-payment” which on the average in these countries is no more than 40 %. In fiscal terms public expenses for pharmaceuticals in Russian Federation as share of GDP are 3,6 times lower and in absolute values (in $PPP per capita per year) are 5,6 times lower than in average in the OECD countries.

In this article is proved, that it’s highly effective to increase the public expenses at the rate of 200 billions rubles on drugs for children and the patients, suffering from circulatory system diseases. One extra ruble invested by the government will generate income by 4,5 rubles. This is achieved thanks to the 1,5% per year increase of the GDP due to the prolongation of pension age, decrease in mortality and morbidity associated days-off among working age population and also due to non direct gains.

Key words. Public spending on outpatient pharmaceuticals, efficiency of investments, expenses on pharmaceuticals, mortality of population, morbidity of population.

References

  1. Evropeyskaya baza dannykh "Zdorove dlya vsekh" [“Health for all” European database] [Internet] [cited 2011 Oct 07]. Available from: http://data.euro.who.int/hfadb/shell_ru.html
  2. Demograficheskiy ezhegodnik Rossii [Demographic Yearbook of Russia]. Moscow: Rosstat; 2011. 525 p.
  3. Doklad o realizatsii Programmy gosudarstvennykh garantiy okazaniya grazhdanam Rossiyskoy Federatsii besplatnoy meditsinskoy pomoshchi v 2010 godu . [Report on realization of the Program on State Guarantees to Deliver Free Medical Care to the Citizens of the Russian Federation in 2010]. Moscow: Minzdravsotsrazvitiya RF; 2011. 40 p.
  4. Zdravookhranenie v Rossii [Health care in Russia]. Moscow: Goskomstat Rossii; 2009. 365 p.
  5. Rossiya v tsifrakh. 2011: Kratkiy statisticheskiy sbornik [Russia in figures. 2011: Brief statistical book]. Moscow: Goskomstat Rossii; 2011. 581 p.
  6. Tezisy k dokladu Ministra Tatyany Golikovoy na Vserossiyskom forume meditsinskikh rabotnikov. [Thesis for T. Golikova’s report at the All-Russia Forum of Healthcare Workers] [Internet]. 2011 [cited 2011 Oct 20]. Available from: http://www.minzdravsoc.ru/health/modernization/19
  7. Ulumbekova G.E. Zdravookhranenie Rossii. Chto nado delat: nauchnoe obosnovanie Strategii razvitiya zdravookhraneniya RF do 2020 goda [Health care of Russia. That is what should be done. Scientific foundation of «The strategy for RF health care development up to 2020»]. Moscow: GEOTAR-Media; 2010. 592 p.
  8. Health at a Glance 2009: OECD Indicators. France: OECD. 2009. 184 p.
  9. Leatherman S., Sutherland K. The Quest for Quality in the NHS. A chartbook on quality of care in the UK. Seattle: The Nuffield Trust. 2005. 183 p.
  10. The NHS Improvement Plan: Putting People at the Heart of Public Services. Norwich:NHS; 2004. 80 p.

Views: 17339

Be first to comment this article

Write Comment
  • Please keep the topic of messages relevant to the subject of the article.
  • Personal verbal attacks will be deleted.
  • Please don't use comments to plug your web site. Such material will be removed.
  • Just ensure to *Refresh* your browser for a new security code to be displayed prior to clicking on the 'Send' button.
  • Keep in mind that the above process only applies if you simply entered the wrong security code.
Name:
E-mail
Comment:

Code:* Code

Last Updated ( Tuesday, 19 November 2013 )
< Prev   Next >
home contact search contact search